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Abstract
 
The importance of mast cells in the development of the allergen-induced airway hyperreactiv-
ity and inflammation associated with asthma remains controversial. We found that genetically
mast cell–deficient WBB6F
 
1
 
-
 
W/W
 
v
 
 mice that were sensitized to ovalbumin (OVA) without
adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker re-
sponses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosino-
phil infiltration, and numbers of proliferating cells within the airway epithelium than did iden-
tically treated WBB6F
 
1
 
-
 
1
 
/
 
1
 
 normal mice. However, 
 
W/W
 
v
 
 mice that had undergone
selective reconstitution of tissue mast cells with in vitro–derived mast cells of congenic 
 
1
 
/
 
1
 
mouse origin exhibited airway responses that were very similar to those of the 
 
1
 
/
 
1
 
 mice. By
contrast, 
 
W/W
 
v
 
 mice that were sensitized with OVA emulsified in alum and challenged with
aerosolized OVA exhibited levels of airway hyperreactivity and lung tissue eosinophil infiltra-
tion that were similar to those of the corresponding 
 
1
 
/
 
1
 
 mice. Nevertheless, these 
 
W/W
 
v
 
mice exhibited significantly fewer proliferating cells within the airway epithelium than did
identically treated 
 
1
 
/
 
1
 
 mice. These results show that, depending on the “asthma model” in-
vestigated, mast cells can either have a critical role in, or not be essential for, multiple features
of allergic airway responses in mice.
Key words: eosinophil • epithelium • hyperresponsiveness • tissue remodeling • T lymphocyte
 
Introduction
 
Asthma is an increasingly prevalent and often severe disease
characterized by chronic inflammation of the airways and
heightened airway reactivity to stimuli of bronchoconstric-
tion (1–5). Patients can exhibit the disorder when exposed
to very small amounts of antigen, indicating that local am-
plification mechanisms can contribute significantly to in-
flammation in this setting (2–7). Tissue mast cells can be
activated to release potent mediators of inflammation by
antibody-dependent mechanisms, and can respond to very
low doses of specific antigen (5, 7). Although mast cells
thus would appear to be well suited to amplify local inflam-
matory responses to antigen challenge, there is considerable
debate about the importance of these cells in the expression
of the features of chronic asthma (7–18).
For example, there is no question that features of chronic
asthma, including airway hyperreactivity to methacholine
and eosinophil infiltration (a characteristic of the chronic
inflammation associated with asthma [2–7]), can be elicited
in mouse models in the absence of IgE antibodies (8, 12),
all antibodies (9–11), or mast cells (14–18). However, it is
also true that airway hyperreactivity can be induced in mice
by IgE- (13, 19) and mast cell–dependent mechanisms (19).
Can these apparently discordant findings be reconciled?
We have hypothesized that mast cells may be critical in
asthma because of their ability to amplify inflammation
through the release of diverse proinflammatory mediators,
and have proposed that this function may be especially im-
portant in settings that otherwise may favor the develop-
ment or expression of relatively weak immunological re-
sponses (7). It is well known that many patients with
asthma can express dramatic pathophysiological responses
to challenge with low doses of specific antigen (20, 21).
However, many protocols used to induce “asthma models”
in mice use sensitization with antigen mixed with an artifi-
cial adjuvant such as alum; this can promote a strong “non-
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specific” antibody response, or have other effects that may
influence features of the asthma model. Therefore, we used
genetically mast cell–deficient and congenic normal mice
to investigate the role of mast cells in two models of
asthma: a conventional model using sensitization with
alum, and a model that omitted this adjuvant.
 
Materials and Methods
 
Mice.
 
Genetically mast cell–deficient WBB6F
 
1
 
-
 
Kit
 
W
 
/Kit
 
W-v
 
(
 
W/W
 
v
 
) mice and the congenic normal WBB6F
 
1
 
-
 
1
 
/
 
1
 
 (
 
1
 
/
 
1
 
)
mice were purchased from The Jackson Laboratory. Adult 
 
W/W
 
v
 
mice ordinarily contain 
 
,
 
1.0% of the number of dermal mast
cells present in the skin of the congenic normal (
 
1
 
/
 
1
 
) mice, and
have no detectable mature mast cells in the respiratory system or
other anatomical sites (22–24). Mice were kept in community
cages at light periods of 12 h, and were fed water and mouse
chow ad libitum. Age-matched animals were used in all individ-
ual experiments, including those comparing groups of 
 
W/W
 
v
 
mice, congenic 
 
1
 
/
 
1
 
 mice, and mast cell–reconstituted 
 
W/W
 
v
 
mice (see below). All animal care and experimentation was con-
ducted in accord with current National Institutes of Health and
Stanford University Institutional Animal Care and Use Commit-
tee guidelines.
 
Mast Cell Reconstitution.
 
Selective reconstitution of mast cells
in mast cell–deficient WBB6F
 
1
 
-
 
W/W
 
v 
 
mice (The Jackson Labo-
ratory) was carried out by the method described by Martin et al.
(19), with slight modification. Suspended bone marrow cells
from WBB6F
 
1
 
-
 
1
 
/
 
1
 
 normal mice were cultured in WEHI-3–
conditioned medium (containing IL-3) for 4–5 wk, at which
time the cell populations were composed of 
 
.
 
95% immature
mast cells, as assessed by staining with toluidine blue. 5 
 
3
 
 10
 
6
 
bone marrow–derived cultured mast cells (BMCMCs)
 
 
 
were in-
fused via the tail vein into each 
 
W/W
 
v
 
 mouse, and the recipients
(BMCMC
 
®
 
W/W
 
v
 
 mice) were studied at least 28 wk later. Re-
constitution of 
 
W/W
 
v
 
 mice with BMCMCs did not repair their
anemia (as determined by hematocrit performed shortly before
the date of study), confirming the selectivity of the mast cell re-
constitution (19, 23, 24). OVA-sensitized, OVA-challenged BM-
CMC
 
®
 
W/W
 
v
 
 mice had 4.2 
 
6
 
 2.9 mast cells/mm
 
2
 
 of peritra-
cheal tissue (versus none or 19.2 
 
6
 
 3.0 for 
 
W/W
 
v
 
 or 
 
1
 
/
 
1
 
 mice,
respectively) and 9.0 
 
6
 
 2.1 mast cells/cm
 
2
 
 of lung tissue (versus
none or 0.4 
 
6
 
 0.1 for 
 
W/W
 
v
 
 or 
 
1
 
/
 
1
 
 mice, respectively).
 
Immunization and Airway Challenge with Antigen.
 
Some mice
were immunized by intraperitoneal injection of 10 
 
m
 
g OVA
(Sigma-Aldrich) in 0.1 ml saline on each of seven alternate days.
40 d after the beginning of the sensitization period, groups of
mice (8–10 mice per group per experiment) received the first of
three intranasal challenges, each 3 d apart, of either 20 
 
m
 
l of saline
(as a control) or 20 
 
m
 
l of saline containing 2, 20, or 200 
 
m
 
g of
OVA. Mice were assessed for airway hyperresponsiveness (AHR)
and airway inflammation 24 h after the last intranasal challenge.
To induce an apparently mast cell–independent model of asthma,
other groups of mice were immunized by intraperitoneal injec-
tion of 20 
 
m
 
g of OVA emulsified in 2.25 mg alum (Imject
 
®
 
Alum;
Pierce Chemical Co.) in a total volume of 200 
 
m
 
l on days 1 and
14 (15). These mice were challenged by the airways with OVA
(1% in saline) for 20 min on days 28, 29, and 30 by ultrasonic
nebulization (15), and were assessed 24 h after the last OVA ex-
posure for AHR and airway inflammation.
 
Measurement of Airway Reactivity.
 
24 h after the final OVA
challenge, bronchial reactivity to aerosolized methacholine was
 
measured using the Buxco whole body plethysmograph (Buxco
Electronics) as described by Hamelmann et al. (25). In brief, un-
restrained conscious mice were placed in whole body plethysmo-
graphic chambers and, after 5 min of stabilization, dose response
curves to aerosolized methacholine were generated. Increasing
concentrations of methacholine were aerosolized for 3 min each,
and mean airway bronchoconstriction readings, as assessed by En-
hanced Respiratory Pause (PenH), were obtained over 10-min
periods. PenH can be conceptualized as the phase shift of the tho-
racic flow and the nasal flow curves; increased phase shift corre-
lates with increased respiratory system resistance. PenH is calcu-
lated by the formula PenH 
 
5
 
 (Te/RT 
 
2
 
1) 
 
3 
 
PEF/PIF, where
Te is expiratory time, RT is relaxation time, PEF is peak expira-
tory flow, and PIF is peak inspiratory flow.
 
Histology.
 
Mice were killed by CO
 
2
 
 inhalation, then lungs
were inflated with 1 ml of air and removed. The right lung of
each mouse was fixed in 10% neutral buffered formalin, whereas
the left lung and trachea were fixed in Carnoy’s fixative. For anal-
ysis of lung eosinophils, formalin-fixed tissues were embedded in
paraffin, and 5-
 
m
 
m sections were stained with Congo red (26).
Total numbers of eosinophils per lung tissue section and perivas-
cular eosinophils were counted at 
 
3
 
400 magnification, and num-
bers were expressed per mm
 
2
 
. For analysis of lung mast cells,
5-
 
m
 
m sections from Carnoy’s or formalin-fixed tissues were
stained with Alcian blue/safranin.
 
Detection of 5-Bromo-2
 
9
 
-Deoxyuridine
 
1
 
 Cells.
 
In some experi-
ments, mice received (
 
1
 
)-5-bromo-2
 
9
 
-deoxyuridine (BrdU; 100
mg/kg) 1 h before sacrifice (27). BrdU
 
1
 
 cells were detected by
standard immunohistochemical procedures using an anti-BrdU
alkaline phosphatase F(ab
 
9
 
)
 
2
 
 fragment (diluted to 0.3 U/ml in
blocking buffer for 1 h; Boehringer); tissues were developed with
Fast Red for 15 min, then counterstained with Mayer’s hematox-
ylin for 20 min. BrdU
 
1
 
 cells within the tracheal or bronchiolar
epithelium were counted, and numbers were expressed per mm
of epithelium.
 
Measurement of OVA-specific and Total IgE and IgG
 
1
 
 Antibodies.
 
Sera were obtained 1 d before antigen challenge in mice that had
been sensitized with OVA alone or with OVA emulsified in alum
(on days 39 or 27 after sensitization, respectively). OVA-specific
IgE and IgG
 
1
 
 levels were measured by ELISA according to the
method described by Spergel et al. (28). Total serum IgE and IgG
 
1
 
levels were measured by ELISA (BD PharMingen).
 
Statistical Analyses.
 
Differences in responses in various groups
of mice were tested for significance by analysis of variance
(ANOVA) for AHR, or by the unpaired Student’s 
 
t
 
 test (two
tailed) for all other features of the models. After determining that
responses of individual groups of mice of specific genotype and
sensitization and challenge protocol did not differ significantly in
replicate experiments, the results were pooled for statistical analy-
ses and for presentation in Figs. 1, 2, and 4. Note that, in mice of
a given 
 
W/W
 
v
 
 or 
 
1
 
/
 
1
 
 genotype, there were no significant age-
related differences in any tested features of the response (AHR,
eosinophil or BrdU
 
1
 
 cell numbers, or IgE or IgG
 
1
 
 responses) in
the older mice that were used for experiments that included a
BMCMC
 
®
 
W/W
 
v
 
 group, compared with the younger mice that
were used in the other experiments.
 
Results and Discussion
 
Mast Cells Can Enhance Allergen-induced Airway Reactivity
to Methacholine.
 
Fig. 1 A shows airway responses to aero-
solized methacholine in genetically mast cell–deficient 
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WBB6F
 
1
 
-W/Wv mice and congenic normal (1/1) mice
that were sensitized with OVA without adjuvant and then
challenged three times intranasally with either saline or 2, 20,
or 200 mg of OVA, each 3 d apart. In each of four separate
experiments, W/Wv mice were significantly less responsive to
aerosolized methacholine, as assessed by PenH readings, than
were the identically treated congenic WBB6F1-1/1 mice.
Note that the lower sensitivity to methacholine of W/Wv
mice in comparison to the congenic normal mice was
detectable even in OVA-sensitized mice that were chal-
lenged intranasally with saline rather than antigen (Fig. 1
A). We reported previously that the “baseline” airway re-
sponses to intravenous methacholine in anesthetized, tra-
cheotomized naive W/Wv mice were very similar to those
in the congenic 1/1 mice (19). In this study, assessment of
baseline PenH responses to aerosolized methacholine in
nonanesthetized mice indicated that naive W/Wv and con-
genic 1/1 mice had virtually identical airway responsive-
ness to methacholine (Fig. 1 B). Moreover, these responses
were altered minimally, if at all, in naive mice that had
been challenged intranasally with saline three times before
methacholine challenge (Fig. 1 B).
Taken together, the results shown in Fig. 1, A and B indi-
cate that in 1/1 but not in W/Wv mice, sensitization with
OVA resulted in an enhancement of AHR to methacholine
that was detectable z1 mo after the end of the period of an-
tigen sensitization. Although the explanation for this inter-
esting finding is not yet clear, the underlying mechanisms
appear to be at least in part mast cell dependent (see below).
In contrast to the results obtained in mice that were sen-
sitized to OVA without alum and then challenged intrana-
sally, W/Wv mice that were sensitized with 20 mg of OVA
emulsified in alum and then challenged with a 1% OVA
solution by aerosol for 20 min on each of three consecutive
days were not significantly less responsive to aerosolized
methacholine than were the identically treated WBB6F1-
1/1 wild-type mice (Fig. 1 C). These results are thus in
accord with those reported by Takeda et al.(15), who pre-
viously investigated this model of sensitization and chal-
lenge in W/Wv and 1/1 mice. Moreover, in contrast to
the results we obtained in the other model of sensitization
and challenge, the responses to methacholine in W/Wv or
1/1 mice that had been sensitized with OVA in alum and
then challenged by aerosol with saline were not signifi-
cantly different (Fig. 1 C). Presumably, the lack of signi-
ficant AHR to methacholine in the saline-challenged,
OVA-sensitized  1/1 mice shown in Fig. 1 C (in contrast
to the saline-challenged OVA-sensitized 1/1 mice shown
in Fig. 1 A) reflects the differences in the details of sensiti-
zation and/or the different routes of saline challenge (intra-
nasal versus aerosol) in the two models of OVA sensitiza-
tion and challenge.
Figure 1. Airway responses to
aerosolized methacholine. (A)
OVA-sensitized W/Wv mice
(open symbols) that were chal-
lenged three times intranasally
with either saline (e) or with 2
mg (h), 20 mg (s), or 200 mg
(n) of OVA were significantly
less responsive to aerosolized
methacholine than were identi-
cally treated WBB6F1-1/1
control mice (filled symbols;
*P , 0.05). Significant differences
from mice of the same genotype
that were challenged with saline
(e, W/Wv; r, 1/1) are indi-
cated by crosses (P , 0.05). (B)
Naive W/Wv mice, 1/1 mice,
or W/Wv mice that were recon-
stituted with BMCMCs (BMC-
MC®W/Wv mice) were tested
with aerosolized methacholine
before (s, W/Wv; d, 1/1; j,
BMCMC®W/Wv) or after (n,
W/Wv;  m,  1/1;  w, BMCM-
C®W/Wv) three intranasal chal-
lenges with saline. Note the dif-
ferent PenH scale in B, compared with those in A, C, and D. (C) Airway responses to aerosolized methacholine in OVA-challenged W/Wv mice that
were sensitized with OVA emulsified in alum (s) were not significantly different from those of identically treated WBB6F1-1/1 mice (d). Significant
differences from mice of the same genotype challenged with saline (e, W/Wv; r, 1/1) are indicated by crosses (P , 0.05). (D) W/Wv mice that were
reconstituted systemically with BMCMCs (BMCMC®W/Wv) 6 mo before OVA sensitization and challenge (.) exhibited PenH responses to aero-
solized methacholine that were not significantly different from those of identically treated WBB6F1-1/1 mice (d), whereas identically treated mast cell–
deficient W/Wv mice (s) had significantly lower PenH responses (*P , 0.05 versus 1/1 or BMCMC®W/Wv groups). Significant differences from
mice of the same type challenged with saline (e, W/Wv; r, 1/1; w, BMCMC®W/Wv are indicated by crosses (P , 0.05) ||: P , 0.05 versus values
for saline-challenged W/Wv or 1/1 mice. Standard errors in A–D are not shown, but were #12.6, 11.9, 11.7, or 18% of the mean values in A (n 5 22
per group), B (n 5 15 per group), C (n 5 10 per group), and D (n 5 10 per group), respectively. QED, every other day.458 Mast Cells Contribute to Multiple Features of an Asthma Model in Mice
To assess the extent to which the differences between
the responses of W/Wv and 1/1 mice shown in Fig. 1 A
represented consequences of the mast cell deficiency of the
W/Wv mice, as opposed to other effects of their mutations
at c-kit, we repeated the experiments in three groups of
age-matched mice: mast cell–deficient W/Wv mice, con-
genic normal (1/1) mice, and W/Wv mice that had un-
dergone selective repair of their mast cell deficiency (BM-
CMC®W/Wv mice). We found that mast cell–deficient
W/Wv mice that were selectively reconstituted with BMC-
MCs z6 mo before OVA sensitization and challenge were
significantly more responsive to aerosolized methacholine
than were the identically treated W/Wv mice; indeed, these
mast cell–reconstituted W/Wv mice gave responses to
OVA that were statistically indistinguishable from those of
the identically treated WBB6F1-1/1 mice (Fig. 1 D).
Mast Cells Contribute to Persistent AHR to Methacholine in
OVA-sensitized Mice Challenged with Saline Instead of Allergen.
In confirmation of the results shown in Fig. 1 A, we found
that OVA-sensitized W/Wv mice that were challenged
with saline rather than antigen were substantially less re-
sponsive to methacholine than were the identically treated
1/1 mice (Fig. 1 D). However, OVA-sensitized, saline-
challenged BMCMC®W/Wv mice exhibited responses to
methacholine that were intermediate between, and signifi-
cantly different from those of either the mast cell–deficient
W/Wv mice or the congenic normal 1/1 mice.
It is of interest that the AHR to methacholine observed
in OVA-sensitized, OVA-challenged 1/1 mice or BMC-
MC®W/Wv mice was statistically indistinguishable,
whereas the AHR to methacholine detected in OVA-sen-
sitized, saline-challenged BMCMC®W/Wv mice was sig-
nificantly less than that observed in the corresponding 1/1
mice. There are at least two possible explanations for the
latter result: (a) the AHR to methacholine observed in
OVA-sensitized, saline-challenged 1/1 mice is only par-
tially dependent on mast cells, with the remaining compo-
nent(s) reflecting mast cell–independent consequences of
the c-kit mutations in W/Wv mice; and (b) the phenome-
non is entirely mast cell dependent, but the weaker expres-
sion of the response in the BMCMC®W/Wv mice reflects
differences between these mice and the 1/1 mice in the
numbers, anatomical distribution, phenotype, or function
of the adoptively transferred mast cells versus the native
mast cell populations of 1/1 mice. Given the practical
constraints of this model system, distinguishing between
these two alternatives may not be easy.
It will be important to elucidate the mechanisms that
contribute to persistent AHR after allergen sensitization. As
described below (see Fig. 2), few or no eosinophils were
detectable in the airways of OVA-sensitized 1/1 mice
that had been challenged with saline rather than OVA.
However, it is possible that the 2-wk period of sensitization
by intraperitoneal injection of OVA every other day in-
duced airway inflammation that had resolved (at least as
could be assessed by standard histological examination) by
the time of saline challenge z1 mo later, but that this tran-
sient inflammation had long-lasting effects on AHR. We
have already reported that systemic IgE-dependent activa-
tion of mast cells by a single intravenous administration of
anti-IgE to naive mice can induce AHR to intravenous
challenge with methacholine (19). Perhaps (a) OVA-spe-
cific IgE and/or IgG1 antibodies, present during the latter
part of the 2-wk period of OVA sensitization, provided
sufficient priming of airway mast cells to permit these cells
to release mediators in response to the final injection(s) of
OVA at the end of the series of seven injections of antigen,
and (b) such repeated, low-level release of mast cell media-
tors can result in a persistent state of AHR to methacho-
line. However, it is not immediately apparent what specific
mast cell–dependent mechanisms might account for the
persistence of the AHR for z1 mo after the last adminis-
tration of antigen.
The Importance of Mast Cells as Amplifiers of Allergen-
induced AHR Can Vary Markedly Depending on the “Asthma
Model” Studied. Taken together, our data indicate that in
an asthma model that omits alum as an adjuvant and em-
Figure 2. Lung tissue eosinophil infiltration. (A)  Total numbers of
eosinophils/mm2 of lung tissue. (B) Eosinophils/mm2 of perivascular tis-
sue. Statistical significance was determined using the unpaired Student’s t
test (two tailed). *P , 0.05, ** P , 0.01, and *** P , 0.001 versus values
for identically treated WBB6F1-1/1 mice; †P , 0.05, ††P , 0.01, and
†††P , 0.001 versus values for identically sensitized but saline-challenged
mice (shown as mice challenged with “0” OVA) of the same genotype.
Numbers of mice per group: n 5 10 for BMCMC ®W/Wv and n 5 10
for W/Wv or 1/1 in the OVA/alum groups, and n 5 24–32 for W/Wv
or 1/1 in the OVA groups.459 Williams and Galli Brief Definitive Report
ploys intranasal challenge with antigen, mast cells can sig-
nificantly enhance AHR to methacholine (Fig. 1, A and
D). Moreover, this mast cell–dependent effect on the AHR
to methacholine can be detected even in OVA-sensitized
mice that have been challenged with saline rather than an-
tigen (Fig. 1, A and D). By contrast, in an asthma model
that employs alum as an adjuvant during sensitization and
uses aerosol challenge with antigen, the slight difference in
AHR to methacholine in antigen-challenged W/Wv and
1/1 mice was not statistically significant (Fig. 1 C), nor
did such OVA/alum-sensitized mice exhibit significant dif-
ferences in their responses to methacholine after saline
challenge (Fig. 1 C).
In a report that appeared while this study was in review,
Kobayashi et al. (29) found that a mast cell–dependent com-
ponent of AHR to intravenous acetylcholine chloride could
be detected 24 h after the final antigen challenge in mice
that had been sensitized with OVA/alum (10 mg OVA ab-
sorbed to 1 mg of alum intraperitoneally on days 0 and 5)
and challenged 12 and 16 d later with aerosolized OVA (5
mg/ml for 10 min). The differences between the results
with OVA/alum-immunized mice in the study by Koba-
yashi et al. (29) and in our experiments may reflect the dif-
ferences in the details of OVA sensitization and challenge—
we used higher doses of OVA for sensitization (20 mg with
2.25 mg alum intraperitoneally on days 1 and 14), as well as
a different protocol for antigen challenge (1% OVA by
aerosol for 20 min on days 28, 29, and 30)—and/or other
differences in the two studies. For example, Kobayashi et al.
(29) measured airway responses to intravenous challenge in
anesthetized, artificially ventilated mice, whereas we mea-
sured airway responses to aerosol challenge in nonanesthe-
tized, spontaneously breathing mice. Indeed, when Koba-
yashi et al. (29) tested a stronger protocol of OVA challenge
(10 mg/ml for 30 min three times a day on days 12, 14, 16,
and 20), they detected no significant differences in the
AHR of 1/1 and W/Wv mice. Nevertheless, the work of
Kobayashi et al. (29) and our study are in accord in showing
that relatively “weak” protocols of antigen sensitization and
challenge can reveal an important contribution of mast cells
to antigen-induced AHR to cholinergic stimulation that
may be masked under other circumstances.
Mast Cells Can Enhance Allergen-induced Increases in Num-
bers of Airway Eosinophils and BrdU1 Cells. To investigate
Figure 3. Histological analysis of lung inflammation. (A) Perivascular inflammation, with eosinophils (some eosinophils are indicated by arrows);
Congo red stain. Original magnification: 3400. The inset in A (BMCMC®W/Wv) shows a higher-magnification view of the area indicated by the two
arrows in order to illustrate eosinophils (granulocytes with red cytoplasm). Original magnification in inset: 3800. (B) BrdU1 cells (red, some indicated
with arrows) within the tracheal epithelium. Immunohistochemistry was developed with Fast Red, with Mayer’s hematoxylin counterstain. (C) BrdU1
cells (red, some indicated with arrows) within the bronchiolar epithelium. (D) Mast cells (Alcian blue–positive cells, some indicated with arrows) in the
trachea. Original magnification in B–D: 3200.460 Mast Cells Contribute to Multiple Features of an Asthma Model in Mice
whether mast cells also contributed to chronic inflamma-
tion of the airways, we examined two features of the re-
sponse: (a) numbers of recruited eosinophils, and (b) num-
bers of cells in the affected airways that had incorporated
the thymidine analogue BrdU, which is indicative of cell
proliferation (26). In accord with the results of Takeda et
al. (15), we found that OVA challenge induced the infiltra-
tion of roughly equivalent numbers of eosinophils, whether
quantified in the entire lung tissue (Fig. 2 A) or in the
perivascular regions (Fig. 2 B), in W/Wv or 1/1 mice that
had been sensitized with OVA and alum. Notably, Koba-
yashi et al. (29) also detected no significant difference in the
extent of eosinophil recruitment (as assessed by quantifica-
tion of eosinophils in bronchoalveolar lavage fluid) in W/Wv
or 1/1 mice that were subjected to protocols of sensitiza-
tion with OVA/alum and antigen challenge that differed
from those used in our study.
By contrast, we found that OVA challenge induced min-
imal eosinophil infiltration in W/Wv mice that had been
sensitized without alum, but the responses in the identically
treated 1/1 mice, especially in the perivascular regions,
approached those in the OVA/alum-sensitized animals
(Fig. 2, A and B). In mice sensitized to OVA without adju-
vant, responses to challenge with 20 mg of OVA were es-
sentially identical in mast cell–reconstituted W/Wv mice
and in 1/1 controls (Fig. 2, A and B; Fig. 3 A).
Many studies have indicated that the airway epithelium
in subjects with asthma exhibits injury and repair, and that
this process is associated with proliferating epithelial cells
(30–32). In our experiments, histological examination indi-
cated that BrdU was incorporated into cells in the tracheal
(Fig. 3 B) and bronchiolar (Fig. 3 C) epithelium, as well as
into cells outside of the airways (Fig. 3, A and B). By mor-
phological criteria, the BrdU1 cells in the epithelium ap-
peared to include both epithelial cells and some infiltrating
mononuclear leukocytes. Although establishing the specific
identity of the various types of BrdU1 cells in this model
will require additional studies, it is clear that mast cells are
important in regulating the total number of BrdU1 cells in
the airway epithelium (Fig. 4). Notably, and in contrast to
our findings with AHR to methacholine (Fig. 1) or eosino-
phil infiltration (Fig. 2), OVA-challenged W/Wv mice ex-
hibited significantly reduced numbers of BrdU1 cells
compared with identically-treated 1/1 mice after OVA
sensitization either with or without alum. As with the two
other features of asthma that we assessed in this model, in
mice sensitized to OVA without adjuvant, numbers of
BrdU1 cells after challenge with 20 mg of OVA were sta-
tistically indistinguishable in mast cell-reconstituted W/Wv
mice and congenic wild-type mice (Fig. 4, A and B).
Figure 4. BrdU1 cells within airway epithelium. (A) BrdU1 cells/mm
of tracheal epithelium. (B) BrdU1 cells/mm of bronchiolar epithelium. 10
bronchioles per section were examined and the average number of BrdU1
cells within the epithelial layer was calculated. *P , 0.05, **P , 0.01, and
***P , 0.001 versus values for identically treated WBB6F1-1/1 mice;
†P , 0.05, ††P , 0.01, and †††P , 0.001 versus values for identically sen-
sitized but saline-challenged mice (shown as mice challenged with “0”
OVA) of the same genotype. Numbers of mice per group are as in Fig. 2.
Table I. OVA-specific and Total IgE and IgG1 Levels in
the Serum
OVA-specific 
Ig Total Ig levels
Genotype Sensitization IgE IgG1* IgE IgG1
(ng/ml) (mg/ml) (mg/ml)
W/WV Naive 2.30 0.06 0.18 1.05
1/1 Naive 3.18 0.05 0.15 1.07
W/WV OVA/alum 64.8‡ 0.65‡ 0.43‡ 35.6‡
1/1 OVA/alum 59.4‡ 0.65‡ 0.56‡ 64.2‡
W/WV OVA 80.8‡ 0.68‡§ 0.54‡ 9.30‡§
1/1 OVA 65.3‡ 0.68‡§ 0.47‡ 8.09‡§
BMCMC
®W/WV
OVA 75.8‡ 0.68‡ 0.50‡ 8.24‡
Mean serum levels of OVA-specific antibodies and total IgE and IgG1
were determined by ELISA.
*OD readings at 405 nm.
‡P , 0.05 (by unpaired Student’s t test) versus values for naive mice of
the same genotype.
§P , 0.05 versus values for OVA/alum-sensitized mice of the same
genotype.461 Williams and Galli Brief Definitive Report
W/Wv and 1/1 Mice Develop Similar IgE and IgG1 Re-
sponses to Antigen Sensitization. W/Wv, 1/1, and BMC-
MC®W/Wv mice developed remarkably similar IgE and
IgG1 antibody responses to OVA sensitization (Table I).
However, mice sensitized with alum developed slightly
lower levels of OVA-specific IgG1, but much higher lev-
els of total IgG1, than did mice sensitized without alum
(Table I).
Conclusions. We have found that the extent to which
mast cells can contribute to the airway hyperreactivity and
chronic inflammation associated with models of allergic
asthma in mice is highly dependent on the specific experi-
mental model investigated. We used two different “asthma
models” to assess three characteristics of the airway re-
sponse to allergen challenge in OVA-sensitized mice: air-
way reactivity to aerosolized methacholine, infiltration of
airway tissues with eosinophils, and numbers of BrdU1
cells in the airway epithelium. For each of these features,
responses to OVA in antigen-challenged mast cell–defi-
cient W/Wv mice that had been sensitized with OVA in
the absence of alum were substantially and significantly
lower than those in the corresponding normal mice, and
responses in mast cell–reconstituted W/Wv mice were sta-
tistically indistinguishable from those in the wild-type ani-
mals. Notably, of six prior studies that employed W/Wv
and 1/1 mice to investigate allergen-induced eosinophil
recruitment to the airways (14–18, 29), only one detected
significantly reduced responses (by z50%) in W/Wv versus
1/1 mice (14). In that study, as in ours, the mice had
been sensitized without an adjuvant (14).
By contrast, we detected no statistically significant effects
of mast cells on either airway reactivity to methacholine or
airway eosinophil infiltration in mice that were sensitized
to OVA with alum. These findings are thus in accord with
those reported by Takeda et al. (15), who investigated the
same asthma model. Using a different (“weaker”) model of
OVA/alum sensitization and OVA challenge, Kobayashi et
al. (29) detected a mast cell–dependent contribution to air-
way hyperreactivity to cholinergic stimulation but not to
eosinophil recruitment.
It will be important to identify the specific mechanisms
by which mast cells can augment airway hyperreactivity,
eosinophil infiltration, and numbers of BrdU1 cells in the
airways, and to characterize the specific epithelial and non-
epithelial cell populations that are affected. Indeed, the
striking increase in BrdU1 cells after allergen challenge rep-
resents a previously unrecognized feature of these asthma
models in mice, and one which may have a mast cell–depen-
dent component whether the mice have been sensitized to
antigen either in the presence or absence of alum. We sus-
pect that multiple mediators and cytokines, and both direct
and indirect mechanisms, may link mast cell activation to
the specific aspects of the airway responses that we have
studied. For example, some “mast cell–dependent” effects
on AHR or numbers of BrdU1 cells could be mediated, at
least in part, by eosinophils. Nevertheless, our data strongly
support the hypothesis that the mast cell can represent an
important local amplifier of antigen-dependent chronic in-
flammation in asthma, and that this cell can contribute sig-
nificantly to multiple features of this disorder.
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